• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecologic Oncology Reports >Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
【24h】

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases

机译：贝伐单抗联合小剂量口服环磷酰胺的节律化疗治疗复发性宫颈癌4例

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Standard chemotherapy for women with advanced or recurrent cervical cancer involves a combination of paclitaxel, platinum, and bevacizumab. However, for patients who experience anaphylaxis in response to paclitaxel or platinum, have permanent peripheral neuropathy, or develop early recurrence or progressive disease during first-line chemotherapy, the development of a non-taxane non-platinum regimen is mandatory. Clinical trials using anti-angiogenic treatment demonstrated favorable outcomes in cases of highly vascularized cervical cancer. Metronomic chemotherapy has been considered an anti-angiogenic treatment, although its use in combination with bevacizumab has not been studied in cervical cancer. We treated four patients with recurrent cervical cancer with 50?mg of oral cyclophosphamide daily and 15?mg/kg of intravenous bevacizumab every 3?weeks (CFA-BEV). One patient experienced disease progression after 4?months, whereas the other three patients continued the regimen until their last follow-up at 13, 14, and 15?months, respectively. One patient suffered from grade 3 neutropenia; however, no grade 2 or higher non-hematological toxicities were observed. These cases demonstrate the use of CFA-BEV with minimal toxicity and expected anti-cancer activity and indicate that this regimen should be considered for second-line chemotherapy in advanced recurrent cervical cancer. Highlights ? Development of non-taxane, non-platinum regimen is warranted in the second line treatment of recurrent cervical cancer. ? Clinical trials using anti-angiogenetic drugs showed better outcomes in cases of highly vascularized cervical cancer. ? Metronomic chemotherapy has been shown to inhibit angiogenesis. ? This is the first case report of metronomic chemotherapy with bevacizumab in cervical cancer.
机译：晚期或复发性宫颈癌女性的标准化疗方案包括紫杉醇，铂和贝伐单抗联合治疗。但是，对于一线化疗中出现对紫杉醇或铂类药物有过敏反应，出现永久性周围神经病变或发生早期复发或进行性疾病的患者，必须制定非紫杉烷类非铂类治疗方案。使用抗血管生成治疗的临床试验表明，在高度血管化的子宫颈癌病例中有良好的预后。节律化疗被认为是抗血管生成的治疗方法，尽管尚未在宫颈癌中研究将其与贝伐单抗联合使用。我们每天用50？mg口服环磷酰胺和每3？周15 mg / kg的贝伐单抗静脉注射治疗4例复发性宫颈癌患者（CFA-BEV）。一名患者在4个月后出现疾病进展，而其他三名患者继续接受治疗，直到他们分别在13个月，14个月和15个月时进行了随访。 1例患有3级中性粒细胞减少症;但是，未观察到2级或更高的非血液学毒性。这些病例证明使用CFA-BEV具有最低的毒性和预期的抗癌活性，并表明对于晚期复发性宫颈癌的二线化疗应考虑采用该方案。强调 ？在复发性宫颈癌的二线治疗中，必须开发非紫杉烷，非铂疗法。 ？使用抗血管生成药物的临床试验显示，在高度血管化的宫颈癌病例中，预后较好。 ？节律性化疗已显示抑制血管生成。 ？这是贝伐单抗在宫颈癌中进行基因组化学疗法的第一例报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号